Abstract
Autoimmune diseases are characterized by the loss of tolerance toward self-antigens and the induction of destructive immune responses leading to tissue damage. Most patients with autoimmune diseases are treated with immunosuppressive drugs that suppress the immune response in a non-specific fashion, which is inevitably accompanied by several side effects. Antigen-specific immunomodulation and patient-tailored therapies are likely to solve these issues and to elicit long-term protection against disease flares. This Viewpoint analyzes the potential use of DC for induction of antigen-specific tolerance in autoimmune disease settings.
| Original language | English |
|---|---|
| Pages (from-to) | 2119-2123 |
| Number of pages | 5 |
| Journal | European Journal of Immunology |
| Volume | 40 |
| Issue number | 8 |
| DOIs | |
| Publication status | Published - Aug 2010 |
Fingerprint
Keywords
- CD103
- DC
- TGF-β
- Tolerance
- TSLP
ASJC Scopus subject areas
- Immunology
- Immunology and Allergy
Cite this
Dendritic cells in tolerance induction for the treatment of autoimmune diseases. / Rescigno, Maria.
In: European Journal of Immunology, Vol. 40, No. 8, 08.2010, p. 2119-2123.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Dendritic cells in tolerance induction for the treatment of autoimmune diseases
AU - Rescigno, Maria
PY - 2010/8
Y1 - 2010/8
N2 - Autoimmune diseases are characterized by the loss of tolerance toward self-antigens and the induction of destructive immune responses leading to tissue damage. Most patients with autoimmune diseases are treated with immunosuppressive drugs that suppress the immune response in a non-specific fashion, which is inevitably accompanied by several side effects. Antigen-specific immunomodulation and patient-tailored therapies are likely to solve these issues and to elicit long-term protection against disease flares. This Viewpoint analyzes the potential use of DC for induction of antigen-specific tolerance in autoimmune disease settings.
AB - Autoimmune diseases are characterized by the loss of tolerance toward self-antigens and the induction of destructive immune responses leading to tissue damage. Most patients with autoimmune diseases are treated with immunosuppressive drugs that suppress the immune response in a non-specific fashion, which is inevitably accompanied by several side effects. Antigen-specific immunomodulation and patient-tailored therapies are likely to solve these issues and to elicit long-term protection against disease flares. This Viewpoint analyzes the potential use of DC for induction of antigen-specific tolerance in autoimmune disease settings.
KW - CD103
KW - DC
KW - TGF-β
KW - Tolerance
KW - TSLP
UR - http://www.scopus.com/inward/record.url?scp=77956132493&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77956132493&partnerID=8YFLogxK
U2 - 10.1002/eji.201040474
DO - 10.1002/eji.201040474
M3 - Article
C2 - 20853497
AN - SCOPUS:77956132493
VL - 40
SP - 2119
EP - 2123
JO - European Journal of Immunology
JF - European Journal of Immunology
SN - 0014-2980
IS - 8
ER -